C:\Program Files\Stnexp\Queries\10685124 (a).str





chain nodes :
7 8 9 10 17
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
chain bonds :
5-7 7-8 8-9 9-10 10-12 13-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
5-7 7-8 8-9 9-10 10-12 11-12 11-16 12-13 13-14 13-17 14-15 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 11 :

G1:O,S,N,CH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS

C:\Program Files\Stnexp\Queries\10685124 (sub).st





chain nodes :
7
ring nodes :
1 2 3 4 5 6
chain bonds :
3-7
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 3-7 4-5 5-6

G1:O,S,N,CH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS

=>
Uploading C:\Program Files\Stnexp\Queries\10685124 (a).str



chain nodes :
7 8 9 10 17
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
chain bonds :
5-7 7-8 8-9 9-10 10-12 13-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
5-7 7-8 8-9 9-10 10-12 11-12 11-16 12-13 13-14 13-17 14-15 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 11 :

G1:O,S,N,CH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N,CH2

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:28:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1457 TO ITERATE

100.0% PROCESSED 1457 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 26851 TO 31429
PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 14:28:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 29039 TO ITERATE

100.0% PROCESSED 29039 ITERATIONS 173 ANSWERS
SEARCH TIME: 00.00.01

L3 173 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10685124 (sub).str





chain nodes :

7
ring nodes :
1 2 3 4 5 6
chain bonds :
3-7
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 3-7 4-5 5-6

G1:O,S,N,CH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



G1 O,S,N,CH2

Structure attributes must be viewed using STN Express query preparation.

=> s l4 sub=l3 sss sam
SAMPLE SUBSET SEARCH INITIATED 14:29:52 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 6 TO 266
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 6 TO 266

L5 6 SEA SUB=L3 SSS SAM L4

=> => s l4 sub=l3 sss ful
FULL SUBSET SEARCH INITIATED 14:30:16 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 98 TO ITERATE

100.0% PROCESSED 98 ITERATIONS 90 ANSWERS
SEARCH TIME: 00.00.01

```
L6            90 SEA SUB=L3 SSS FUL L4

=> s l3 not l6
L7            83 L3 NOT L6

=> => s l7
L8             2 L7

=> d l8 1-2 bib,ab,hitstr
```

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:868427 CAPLUS
DN 136:6016
TI Preparation of aminoalkyllactams as muscarinic receptor antagonists
IN Dvorak, Charles Alois; Fisher, Lawrence Emerson; Green, Keena Lynn; Harris, Ralph New, III; Maag, Hans; Prince, Anthony; Repke, David Bruce; Stabler, Russell Stephen
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

Appl PCT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090081	A1	20011129	WO 2001-EP5584	20010516
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, CZ, DE, DK, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2409841	AA	20011129	CA 2001-2409841	20010516
	EP 1289965	A1	20030312	EP 2001-980030	20010516
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011061	A	20030415	BR 2001-11061	
	JP 2003534330	T2	20031118	JP 2001-586270	20010516
	NZ 522411	A	20040528	NZ 2001-522411	20010516
	RU 2241702	C2	20041210	RU 2002-133208	20010516
	AU 782191	B2	20050707	AU 2002-10122	20010516
	US 2002004501	A1	20020110	US 2001-862286	20010516
	US 6667301	B2	20031223		20010522
	ZA 2002008895	A	20040219	ZA 2002-8895	
	US 2003109524	A1	20030612	US 2002-289055	20021101
	US 6645958	B2	20031111		20021106
	ZA 2002009029	A	20040206	ZA 2002-9029	
	NO 2002005640	A	20030122	NO 2002-5640	20021106
	US 2004034018	A1	20040219	US 2003-632734	20021122
	US 6818645	B2	20041116		20030801
	US 2004087581	A1	20040506	US 2003-685124	20031014
PRAI	US 2000-207483P	P	20000525		
	US 2001-267579P	P	20010209		
	US 2001-267617P	P	20010209		
	WO 2001-EP5584	W	20010516		
	US 2001-862286	A3	20010522		
	US 2001-862522	A3	20010522		
	US 2002-289055	A3	20021106		

OS MARPAT 136:6016
AB Preparation of aminoalkyllactams (I) (one of X, Y or Z = independently -S-,-O-, CH2- or >N-R6, the others are -CH2-; m = 0-3; n = 1-6; R4 = alkyl; R5 = alkyl, alkenyl, alkynyl or cycloalkyl; and R1, R2, and R3 = H or specified substituents). Thus, I (R1 = 4-MeO; R2, R3 = H; R4 = Me; R5 = Et; n = 1; m = 0; X, Y, Z = CH2) (II) is prepared by reaction of (2-oxo-pyrrolidinyl)acetaldehyde with [2-(4-methoxyphenyl)-1-

methyethyl]ethylamine and sodium triacetoxyborohydride in 1,2-dichloroethane. II shows pKi of 7.32, 6.95 and 5.36 in muscarinic (M2, M3, M5) inhibitory activity against hamster ovary cells. I are generally muscarinic M2/M3 receptor antagonists and formulations are given for treating diseases associated with smooth muscle disorders.

IT **376577-81-0P 376577-86-5P 376577-90-1P**
376577-92-3P 376577-94-5P 376577-96-7P
376577-97-8P 376577-98-9P 376577-99-0P
376578-00-6P 376578-03-9P 376578-04-0P
376578-12-0P 376578-13-1P 376578-14-2P
376578-15-3P 376578-21-1P 376578-23-3P
376578-24-4P 376578-25-5P 376578-63-1P
376578-64-2P 376578-66-4P 376578-67-5P
376578-69-7P 376578-74-4P 376578-75-5P
376578-78-8P 376578-82-4P 376579-69-0P
376579-71-4P 376579-73-6P 376579-75-8P
376579-77-0P 376579-79-2P 376579-81-6P
376579-83-8P 376579-85-0P 376579-87-2P
376579-89-4P 376579-91-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkyllactams as muscarinic receptor antagonists)

RN 376577-81-0 CAPLUS
CN 2H-1,3-Oxazin-2-one, 3-[4-[ethyl[(1S)-1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 376577-86-5 CAPLUS
CN 2H-1,3-Oxazin-2-one, 3-[4-[ethyl[1-methyl-2-[4-[(trifluoromethyl)sulfonyl]phenyl]ethyl]amino]butyl]tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376577-90-1 CAPLUS
CN 2H-1,3-Thiazin-2-one, 3-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376577-92-3 CAPLUS
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with 1-[4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl]tetrahydro-2(1H)-pyrimidinone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 376577-91-2
CMF C20 H33 N3 O2



CM 2

CRN 2743-38-6
CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).



RN 376577-94-5 CAPLUS
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with 1-[4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl]tetrahydro-3-methyl-2(1H)-pyrimidinone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 376577-93-4
CMF C21 H35 N3 O2



CM 2

CRN 2743-38-6
CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).



RN 376577-96-7 CAPLUS
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with

tetrahydro-1-methyl-3-[4-[[1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl]propylamino]butyl]-2(1H)-pyrimidinone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 376577-95-6
CMF C22 H34 F3 N3 O



CM 2

CRN 2743-38-6
CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).



RN 376577-97-8 CAPLUS
CN 2(1H)-Pyrimidinone, tetrahydro-1-[4-[[1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl]propylamino]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376577-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, tetrahydro-1-methyl-3-[4-[[1-methyl-2-(2-naphthalenyl)ethyl]propylamino]butyl]-, monohydrochloride (9CI) (CA INDEX

NAME)



● HCl

RN 376577-99-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-[[2-(4-chlorophenyl)-1-methylethyl]propylamino]propyl]tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-00-6 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[4-[ethyl[(1S)-1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 376578-03-9 CAPLUS
CN 2(1H)-Pyrimidinone, tetrahydro-1-[4-[[1-methyl-2-[4-(2-thiazolylsulfonyl)phenyl]ethyl]propylamino]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-04-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[4-[ethyl[1-methyl-2-[4-(2-thiazolylsulfonyl)phenyl]ethyl]amino]butyl]tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-12-0 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-[(trifluoromethyl)sulfonyl]phenyl]ethyl]amino]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-13-1 CAPLUS

CN Benzenesulfonamide, N-methyl-4-[2-[[4-(2-oxo-1-piperazinyl)butyl]propylamino]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-14-2 CAPLUS
CN Piperazinone, 1-[4-[[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]propylamino]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-15-3 CAPLUS
CN Piperazinone, 1-[4-[[1-methyl-2-[4-(2-thiazolylsulfonyl)phenyl]ethyl]propylamino]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-21-1 CAPLUS
CN Piperazinone, 1-[4-[[2-[4-(1,1-dimethylethyl)phenyl]-1-methylethyl]ethylamino]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-23-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 376578-24-4 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-25-5 CAPLUS
CN Morpholine, 4-[[4-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-3-oxo-1-piperazinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-63-1 CAPLUS
CN Piperazinone, 4-methyl-1-[4-[[1-methyl-2-[4-(2-thiazolylsulfonyl)phenyl]ethyl]propylamino]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-64-2 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(2-thiazolylsulfonyl)phenyl]ethyl]amino]butyl]-4-(3-pyridinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-66-4 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-[(trifluoromethyl)sulfonyl]phenyl]ethyl]amino]butyl]-4-(3-pyridinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-67-5 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-[(trifluoromethyl)sulfonyl]phenyl]ethyl]amino]butyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-69-7 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-(3-pyridinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-74-4 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl]amino]butyl]-4-(3-pyridinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-75-5 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-[(trifluoromethyl)sulfonyl]phenyl]ethyl]amino]butyl]-4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 376578-78-8 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl]amino]butyl]-4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 376578-82-4 CAPLUS
CN Piperazinone, 4-methyl-1-[4-[[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]propylamino]butyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 376579-69-0 CAPLUS
CN Piperazinone, 4-[[2-(dimethylamino)ethyl]sulfonyl]-1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-68-9
CMF C24 H42 N4 O5 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-71-4 CAPLUS
CN Piperazinone, 4-[[2-(diethylamino)ethyl]sulfonyl]-1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-70-3
CMF C26 H46 N4 O5 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-73-6 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-[[2-[(1-methylethyl)amino]ethyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-72-5
CMF C25 H44 N4 O5 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-75-8 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-[[2-(1-pyrrolidinyl)ethyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-74-7
CMF C26 H44 N4 O5 S2

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-77-0 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-[[2-[(phenylmethyl)amino]ethyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-76-9
CMF C29 H44 N4 O5 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-79-2 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-[[2-[methyl(phenylmethyl)amino]ethyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-78-1
CMF C30 H46 N4 O5 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-81-6 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-[[2-[(2-hydroxyethyl)amino]ethyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-80-5
CMF C24 H42 N4 O6 S2

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-83-8 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-[[2-[(2-methoxyethyl)amino]ethyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-82-7
CMF C25 H44 N4 O6 S2

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-85-0 CAPLUS
CN Glycine, N-[2-[[4-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-3-oxo-1-piperazinyl]sulfonyl]ethyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-84-9
CMF C25 H42 N4 O7 S2

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-87-2 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-[[2-(1-piperazinyl)ethyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-86-1
CMF C26 H45 N5 O5 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-89-4 CAPLUS
CN Piperazinone, 1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-4-[[2-(4-methyl-1-piperazinyl)ethyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-88-3
CMF C27 H47 N5 O5 S2

PAGE 1-A



PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 376579-91-8 CAPLUS
CN Piperazinone, 4-[(2-aminoethyl)sulfonyl]-1-[4-[ethyl[1-methyl-2-[4-(methylsulfonyl)phenyl]ethyl]amino]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 376579-90-7
CMF C22 H38 N4 O5 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **376581-05-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminoalkyllactams as muscarinic receptor antagonists)
RN 376581-05-4 CAPLUS
CN 2H-1,3-Oxazin-2-one, 3-[4-[ethyl[(1S)-1-methyl-2-[4-(methylthio)phenyl]ethyl]amino]butyl]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1977:29756 CAPLUS
DN 86:29756
TI Studies in potential filaricides: Part VIII. Synthesis of 1-ethyl-3-(2-dialkylaminoethyl)- and 1,3-diethyl-4-dialkylaminomethylhexahydropyrimidin-2-ones
AU Singh, Harindra; Sharma, Satyavan; Iyer, R. N.; Anand, Nitya
CS Cent. Drug Res. Inst., Lucknow, India
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1976), 14B(7), 528-31
CODEN: IJSBDB; ISSN: 0376-4699
DT Journal
LA English
AB The title compds. I (R = H, Me, Et, PhCH2) and II (R = Me, Et) were prepared Thus PhCH2NMeCH2CH2NHCH2CH2CO2Et was aminated with EtNH2 followed by reduction to give PhCH2NMeCH2CH2NHCH2NEtCO2Et, which was cyclized with NaOEt to give I (R = PhCH2). I (R = Me) reduced the microfilarial count in rats infected with Litomosides carinii by 90%.
IT **61322-07-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 61322-07-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-ethyltetrahydro-3-[2-[methyl(2-phenylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



```
=> => d his

     (FILE 'HOME' ENTERED AT 14:27:37 ON 25 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 14:27:46 ON 25 SEP 2005
L1             STRUCTURE UPLOADED
L2           8 S L1 SSS SAM
L3         173 S L1 SSS FUL
L4             STRUCTURE UPLOADED
L5           6 S L4 SSS SAM SUB=L3
L6          90 S L4 SSS FUL SUB=L3
L7          83 S L3 NOT L6

     FILE 'CAPLUS' ENTERED AT 14:30:26 ON 25 SEP 2005
L8           2 S L7

     FILE 'CAOLD' ENTERED AT 14:31:00 ON 25 SEP 2005

=> s l7
L9           0 L7

=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.43     211.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00      -1.46

STN INTERNATIONAL LOGOFF AT 14:31:11 ON 25 SEP 2005
```